

FOR IMMEDIATE RELEASE

Bio Vitos Ltd Provides Update on Potential London Listing, Shareholder Value Protection and Key Clinical Milestones

LONDON, UK — 10 October 2026 — Bio Vitos Ltd ("Bio Vitos" or "the Company") today issued an operational update on its international growth strategy, including ongoing discussions regarding a potential listing on the London Stock Exchange, an intended 12-month share transfer framework to protect shareholder value, and upcoming milestones for its clinical programmes FE-MININ and MAXFERMAN.

AT A GLANCE

NDA signed

with a company listed on the LSE Main Market regarding a potential RTO

£1.50

intended minimum sale price per share for 12 months

~2 months

expected peer review of FE-MININ publication

15 Jan 2027

planned start of the MAXFERMAN study (80 men, 6 weeks)

— Potential London listing via reverse takeover

Bio Vitos has signed a Non-Disclosure Agreement (NDA) with a company listed on the Main Market of the London Stock Exchange. The parties are in discussions regarding a potential transaction, structured as a Reverse Takeover (RTO), that could result in Bio Vitos becoming a publicly listed company in London.

Under the terms of the NDA, the Company cannot at this stage disclose the name of the counterparty or the details of the proposed transaction. Bio Vitos is awaiting formal confirmation of the next steps and the definitive transaction timeline, and will inform shareholders as soon as confidentiality obligations permit.

The Company's ambition is to create a long-term, international and liquid market for Bio Vitos shares while safeguarding the interests of all shareholders.

— Intended 12-month share transfer framework

In light of the ongoing process, the Board intends to introduce a pre-emption procedure for share transfers for a period of 12 months. The aim is to protect the Company's valuation and prevent sales at very low prices that could give a misleading picture of Bio Vitos' market value and adversely affect the ongoing capital raise and listing process.

The intended principles are:

- A minimum intended sale price of **£1.50 per share**.
- All shareholders may sell their shares during the 12-month period, provided the sale is at £1.50 per share or higher and in accordance with the share transfer terms to be introduced.
- Sales above £1.50 per share remain possible.
- After 12 months, the intention is that shares may be transferred freely without this price restriction.

The £1.50 level reflects the Board's view of a reasonable minimum price at the current stage, taking into account the Company's development, its clinical research programmes and the international financing and listing opportunities under discussion. It is an intended minimum sale level, not a guarantee of the shares' market value or that buyers will be available at that price. The transfer terms will be established and implemented in accordance with the Company's Articles of Association and applicable UK law.

— Clinical portfolio advancements

FE-MININ. The clinical study has entered the scientific publication process for international medical journals. The university's formal academic peer review is underway and is expected to take approximately two months.

MAXFERMAN. The formal ethics application is scheduled for submission next week. Recruitment of 80 male participants is planned to begin in December 2026, with the study expected to commence on or about 15 January 2027. The six-week study will use a double daily dose compared with the previous female cohort study. The Company targets publication of the full data before summer 2027.

— Corporate outlook

"We are entering a pivotal phase for Bio Vitos, with two major clinical milestones immediately ahead of us. In parallel, we are pursuing our international fundraising and a potential London listing, with a clear goal: to develop Bio Vitos into an internationally listed life sciences company and create long-term value for our shareholders. We look forward to updating the market as concrete developments materialise."

— Cato Crogh, Chairman of the Board, Bio Vitos Ltd

#

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding a potential listing of Bio Vitos Ltd on the London Stock Exchange, the outcome of RTO discussions, the intended share transfer framework, and the timing and publication of the FE-MININ and MAXFERMAN clinical studies. These statements are based on current expectations and assumptions, and actual results may differ materially. There can be no assurance that any transaction will be completed. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

ABOUT BIO VITOS LTD

Bio Vitos Ltd is a clinical-stage life sciences company dedicated to developing innovative medical solutions and expanding its international research footprint.

MEDIA & INVESTOR RELATIONS

Bio Vitos Ltd Corporate Office
E-mail: info@biovitos.com
Web: www.biovitos.com